Is EZ Detect Stool Test Effective for Colorectal Cancer Screening?
No, EZ Detect is not recommended as a screening method for colorectal cancer in average-risk adults. Major guidelines do not include EZ Detect among approved screening options, and the limited available evidence shows inferior performance compared to guideline-recommended stool-based tests.
Why EZ Detect Falls Short
The most recent and authoritative guidelines from the American Cancer Society 1, American College of Physicians 2, 3, and US Preventive Services Task Force 4 consistently recommend specific stool-based tests for colorectal cancer screening:
- Fecal immunochemical test (FIT) annually
- High-sensitivity guaiac-based fecal occult blood test (gFOBT) annually
- Multitarget stool DNA test every 3 years
EZ Detect is conspicuously absent from all major guideline recommendations 1, 2, 1, 4, 3.
The Evidence Against EZ Detect
The limited research on EZ Detect reveals significant performance problems:
Poor Sensitivity for Advanced Adenomas
A 2007 study found EZ Detect had significantly worse diagnostic accuracy for advanced adenomas (86.0%) compared to standard Hemoccult II testing (94.2%, P=0.01) 5. This is critical because detecting and removing advanced adenomas is a primary mechanism by which screening prevents colorectal cancer.
Unacceptably Low Cancer Detection
A 2014 Thai study demonstrated that EZ Detect had only 41% sensitivity for detecting colorectal cancer (95% CI: 31-51%) 6. This means it missed nearly 6 out of 10 cancers. The sensitivity was particularly poor for:
- Stage I cancers: 29%
- Stage II cancers: 32%
- Infiltrative lesions: 0% (missed all 9 cases)
While specificity was high at 97%, the overall accuracy was only 70% 6—far below what is needed for effective screening.
What You Should Recommend Instead
For average-risk adults aged 45-75 years, offer one of these guideline-endorsed options 1:
Stool-Based Tests (First-Tier Options):
- FIT annually: Strong evidence from randomized trials showing mortality reduction
- High-sensitivity gFOBT annually: Proven mortality benefit in multiple RCTs
- Multitarget stool DNA test every 3 years: FDA-approved with demonstrated detection rates
Visual Examinations (First-Tier Options):
- Colonoscopy every 10 years: Most sensitive for detecting adenomas and cancer
- CT colonography every 5 years: Appropriate alternative when colonoscopy declined
- Flexible sigmoidoscopy every 5 years: Strong evidence for mortality reduction
Key Screening Principles
Start screening at age 45 years for average-risk adults (qualified recommendation) or age 50 years (strong recommendation) 1.
Continue through age 75 years in adults with life expectancy >10 years 1, 2, 1.
Stop screening after age 75 years in most adults, as harms outweigh benefits 2, 3. The average time to prevent one colorectal cancer death is 10.3 years, making screening unlikely to benefit those with limited life expectancy 2.
All positive non-colonoscopy tests require timely follow-up colonoscopy 1.
Common Pitfalls to Avoid
Don't use EZ Detect simply because patients find it convenient. The 2007 study showed 92% patient preference for EZ Detect 5, but patient preference cannot override inadequate clinical performance.
Don't accept suboptimal screening tests. The American College of Physicians explicitly recommends against using stool DNA, serum, or urine tests not validated in guidelines 3.
Don't screen with single-sample tests obtained during digital rectal examination—this is inadequate 7.
The Bottom Line
Choose FIT or high-sensitivity gFOBT for stool-based screening, or offer colonoscopy as a visual examination option. These tests have robust evidence from randomized controlled trials demonstrating reduced colorectal cancer incidence and mortality 1, 2, 1, 4. EZ Detect lacks this evidence base and demonstrates inferior performance characteristics that make it unsuitable for colorectal cancer screening in clinical practice.